Blog

 More than four decades after the advent of insecticide-treated nets (ITNs) and indoor residual spraying (IRS), as well as a plethora of antimalarial drugs, malaria remains one of the most burdensome infectious diseases in the world, killing thousands and infecting millions every year, especially in sub-Saharan Africa. Efforts to combat this mosquito-borne disease via traditional […]

 Malaria is one of the most devastating global public health burdens, in particular in sub-Saharan Africa. From the dawn of history, human beings have waged an uphill battle against this devastating disease. Despite remarkable progress in the long battle against malaria, based on antimalarial drugs, bed nets, and insecticides (indoor residual spraying), the disease continues

 Malaria continues to be one of the greatest global health challenges with more than 200 million cases reported annually and significant mortality, especially in children under five and pregnant women. The continuous search for novel vaccines and therapies is the only option for combating this debilitating disease. Moreover, monoclonal antibodies (mAbs) are promising tools against

 Malaria is one of the world’s most complex health challenges and causes millions of infections annually with significant morbidity and mortality, especially within sub-Saharan Africa. Despite decades of parasite and vector control, drug resistance and inadequate vector control continue to threaten control and elimination efforts. Monoclonal antibodies (mAbs) have shown promise in fighting malaria, and

 Monoclonal antibodies (mAbs) play an important role in the treatment of different diseases including various tumors, and autoimmune and infectious diseases. They specifically inactivate pathogens and agents of disease thus revolutionising modern medicine. What are mAbs, and how do they develop and function in humans? This article reviews the development of mAbs, their mechanism of

 Malaria is a worldwide health concern with sub-Saharan Africa being particularly vulnerable to the disease although success in drug therapy and prophylaxis has made huge inroads into the (previously) devastating disease. The story of malaria is a tale of the human body at war with a destructive evolutionary pathogen, and, although significant achievements have been

 Malaria remains a major public health issue in particular in sub-Saharan Africa where the disease causes substantial morbidity and mortality in populations at large. Conventional approaches to malaria prevention and treatment, such as the use of insecticide-treated nets (ITNs), indoor residual spraying (IRS), and artemisinin-based combination therapies (ACTs), are effective but fall short when it

 Monoclonal antibodies (mAb) are a class of therapeutics that has shown a propensity for successfully treating several diseases including cancer, autoimmune disorders, and some infectious diseases. Monoclonal antibodies typically undergo a long journey from bench-top research until they reach the prescription pad of a physician in a clinical setting. This paper will investigate the long

 Malaria continues to be a public health problem in many countries in tropical and subtropical regions of the world, especially in remote and rural areas where healthcare infrastructure is often lacking. Mobile malaria workers are positioned with the responsibility of providing healthcare services in these hard-to-reach areas. However, transportation challenges can profoundly limit the effectiveness

 Accurate and timely diagnosis and effective treatment are the foundation of malaria control. In circumstances where there is limited access to formal healthcare, the use of mobile malaria workers (MMWs) can be part of a critical health intervention to identify, treat, and follow up malaria cases to reduce morbidity and mortality in areas where the